Matinas BioPharma's at-the-market sales pact with BTIG terminated
BTIG ended the $50 million equity sales agreement effective immediately, with no penalties owed by Matinas.
Matinas BioPharma Holdings disclosed in a Form 8-K that its at-the-market sales agreement with BTIG, LLC has been terminated. BTIG notified the company on July 23, 2026 that it was ending the agreement immediately, acting under Section 12(a) of the contract.1
The agreement dated back to July 2, 2020. Under that original arrangement, Matinas could sell up to $50,000,000 in common stock over time through BTIG in what are known as at-the-market offerings under Rule 415 of the Securities Act of 1933.1
The company said the termination carries no financial cost. Matinas stated it owes no termination penalties or other related expenses as a result of ending the deal.1
For further detail on the original terms, Matinas pointed investors back to the source document. The company noted that the summary in this filing is not exhaustive and that the full terms are available in the exhibit attached to its July 2, 2020 Form 8-K filing with the SEC.1
The filing was signed by Chief Executive Officer Jerome D. Jabbour and dated July 24, 2026. No further details on the reason for termination or any replacement financing arrangement were disclosed in this filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.